Creative Medical Technology Holdings issues mid-year update press release

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc.

CELZ

0.00
  • Creative Medical Technology Holdings issued a mid-year 2026 update, citing progress across its regenerative medicine pipeline and AI-enabled biodefense platform.
  • Olastrocel (CELZ-201) posted positive interim 180-day ADAPT data in chronic lower back pain; FDA cleared an expanded cohort now over 85% enrolled.
  • Ultrasome knee osteoarthritis pilot hit its primary endpoint with 93% showing clinically meaningful improvement; next-stage multi-center study planning underway.
  • Project PHOENIX moved into nationwide AI-enabled virtual data collection targeting at least 1,000 veterans to build the Toxic Exposure Atlas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010900PRIMZONEFULLFEED9755352) on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.